Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.40    0.00 (0.00%)
Bid:
7.30
Ask:
7.50
Spread: 0.20 (2.74%)
Market Cap: £3.24m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Trading Update

28 Apr 2025 07:00

RNS Number : 3659G
Feedback PLC
28 April 2025
 

 

 

The information contained within this announcement is deemed by the Company to constitute inside information pursuant to Article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Feedback plc

 

Trading Update

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, provides a trading update for the year-ended 31 May 2025 (the "Period").

 

The backdrop of the merging of NHS England ("NHSE") with the Department of Health and Social Care ("DHSC"), and the drive for a 50% reduction of operational costs across NHS Trusts and Integrated Care Boards ("ICBs") at a national level, in addition to multiple changes to funding programmes being announced by the government and the NHS, have resulted in increased levels of near-term uncertainty and a delay in expected contract awards.

 

Revenue for the Period is now expected to be c. £0.9m (2024: £1.18m). The Company continues to conservatively manage its finances and remains well funded with cash and short-term investments of £6.6m as at 31 March 2025 following the successful £6.1m (gross) fundraise in November 2024.

 

Changing Environment

For NHS 2025/26, the Elective Recovery Fund ("ERF") has now been rolled into wider NHS funding and no longer exists as a dedicated fund with a national price for diversion payments. The ERF has been replaced by a fixed funding allocation to ICBs for elective recovery (totalling £5.3bn* for 2025/26), linked to ICB indicative activity plans which we believe must be submitted by 31 May 2025, and places increased pressure on ICBs to deliver activity within a fixed financial envelope.

 

The end of the national price for diversion payments under ERF provides greater contracting flexibility between the Company and ICBs as it stands to be paid for every patient hosted on the platform instead of linking payment to the number of successful diversions, aligning to Feedback's standard G-Cloud pricing and licencing model. The Company believes the increased financial pressures and simpler model of licensing will make its products more compelling and accessible to customers and remains confident that once the current landscape settles, ICBs will be positioned to finalise budgeting decisions.

 

Continued Opportunity

The Company continues to progress contract conversations with a growing number of ICBs at a local level and remains positive about the broader environment and opportunity - especially with the continued focus on waitlist rationalisation within the NHS, and the compelling workflow and cost benefits that Feedback provides. The increasing focus on digitisation and the flexibility of the Company's solutions - which can be tailored to the broader changing landscape, underpin management's confidence that Feedback remains positioned to generate strong returns. Together with our primary care partner the Company continues to pursue opportunities linked to the government's Neighbourhood Health model which we believe is likely to form a key component of the NHS 10-Year plan and lead to opportunities later in the year.

 

Dr Tom Oakley, CEO of Feedback plc, said: "With ICBs focusing on cost reductions and operational efficiency we believe that there will be increasing need for innovative productivity solutions such as Bleepa. While there is an element of turmoil, ICBs and Trusts will remain critical in commissioning. We believe that there will be increased clarity on the NHS position as we head into the summer, following the publication of the 10-year plan and Spending Review and that these, along with the submission of ICB indicative activity plans, will create the stability to allow NHS organisations to contract with providers such as Feedback.

 

"We remain excited by the opportunity and were delighted that along with Queen Victoria Hospital NHS Foundation Trust ("QVH") we were recently awarded the 'Most Effective Contribution to Clinical Redesign Award' at the HSJ Partnership Awards 2025 for reducing patient wait times and unnecessary hospital appointments through a digital breathlessness pathway. The recognition for significantly reducing waiting times for patients, improving productivity for NHS staff and reducing unnecessary appointments provides a strong reference point for the wider market."

 

* NHS England » Allocation of resources 2025/26

--Ends--

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Anesh Patel, CFO

+44 (0) 20 3997 7634

IR@fbk.com

 

Panmure Liberum Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley/Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 

Walbrook PR Ltd;

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Nick Rome/Joe Walker

07748 325 236 or 07407 020 470

 

 

About Feedback plc

 

Feedback plc liberates the data and knowledge from multiple healthcare IT systems and delivers better workflow to enable clinicians to communicate, collaborate and provide the best healthcare for their patients. We connect care settings with diagnostic and other relevant data to drive better, faster, safer decision that improve outcomes for patients.

 

By linking different clinical systems together into a seamless view of the patient, we can streamline patient pathways and deliver a digital health and diagnostics record across multiple care providers.

 

Bleepa® is our communication and collaboration platform that displays clinical results at a certified and regulated quality, which enables multi-disciplinary team working and diagnostic-enhanced advice and guidance. CareLocker® is our patient-facing platform that gives patients access and control over their diagnostic and other clinical data.

 

The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

 

https://fbk.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBIGDSIUDDGUR
Date   Source Headline
10th Sep 20187:00 amRNSTexRAD® ordered by Samsung Medical Centre in Seoul
17th Aug 20182:02 pmRNSDirector/PDMR Shareholding
15th Aug 20187:00 amRNSFirst GE Healthcare order for TexRAD®
1st Aug 20181:19 pmRNSDirector/PDMR Shareholding
20th Jul 20187:00 amRNSDirectorate Change
6th Jul 20187:00 amRNSJoint broker update
29th Jun 20183:20 pmRNSDirector/PDMR Shareholding
27th Jun 20187:00 amRNSGrant of Options and Director/PDMR Dealing
22nd Jun 20182:10 pmRNSResult of General Meeting
8th Jun 201810:36 amRNSHolding(s) in Company
7th Jun 20187:05 amRNSNotice of General Meeting
7th Jun 20187:00 amRNSRevised strategy to build a global company
1st Jun 20187:00 amRNSAppointment of new Medical Director
10th May 20189:27 amRNSHolding(s) in Company
4th May 20186:09 pmRNSHolding(s) in Company
1st May 20187:00 amRNSDirector/PDMR Shareholding
30th Apr 20185:00 pmRNSTotal Voting Rights
27th Apr 20187:00 amRNSTwo-year contract with Royal Papworth Hospital
25th Apr 20182:05 pmRNSSecond Price Monitoring Extn
25th Apr 20182:00 pmRNSPrice Monitoring Extension
25th Apr 20187:00 amRNSDistribution agreement with GE Healthcare
17th Apr 20187:00 amRNSHolding(s) in Company
16th Apr 20187:30 amRNSNew Company Structure and Directorate Change
16th Apr 20187:25 amRNSAppointment of non-executive director
9th Apr 20182:39 pmRNSHolding(s) in Company
29th Mar 20187:00 amRNSEquity Fundraising to raise £440,000
21st Mar 20189:01 amRNSHolding(s) in Company
16th Mar 20185:11 pmRNSHolding(s) in Company
16th Mar 20187:00 amRNSDirectorate Change
8th Mar 20188:48 amRNSHolding(s) in Company
7th Mar 20182:39 pmRNSHolding(s) in Company
1st Mar 20181:03 pmRNSHolding(s) in Company
26th Feb 20187:00 amRNSHalf-year Report
14th Feb 20187:00 amRNSDirectorate Change
9th Feb 201812:04 pmRNSHolding(s) in Company
5th Feb 20181:56 pmRNSHolding(s) in Company
28th Dec 20175:42 pmRNSHolding(s) in Company
28th Dec 20175:19 pmRNSTotal Voting Rights
20th Dec 20179:33 amRNSHolding(s) in Company
30th Nov 20174:38 pmRNSResult of AGM
22nd Nov 20179:37 amRNSHolding(s) in Company
22nd Nov 20177:00 amRNSPresentation at RSNA 2017
20th Nov 201712:40 pmRNSHolding(s) in Company
20th Nov 20177:00 amRNSFirst CE marked release of TexRAD® technology
7th Nov 20177:00 amRNSFinal Results
14th Sep 20177:00 amRNSHolding(s) in Company
31st Jul 20175:00 pmRNSTotal Voting Rights
28th Jul 201710:53 amRNSCCI Exclusive Distributor agreement with Boya
30th Jun 20172:21 pmRNSHolding(s) in Company
30th Jun 201712:41 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.